About ARTBIO
ARTBIO is a company based in Sacramento (United States) founded in 2021 by Roy H Larsen and Oyvind Bruland.. ARTBIO has raised $245.3 million across 3 funding rounds from investors including ARE, Third Rock Ventures and F-Prime Capital. ARTBIO offers products and services including AB001, AlphaDirect TM, and Pipeline Programs. ARTBIO operates in a competitive market with competitors including Advanced Accelerator Applications, SOFIE, AdvanCell, Ariceum Therapeutics and Mariana Oncology, among others.
- Headquarter Sacramento, United States
- Founders Roy H Larsen, Oyvind Bruland
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Artbio Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$245.3 M (USD)
in 3 rounds
-
Latest Funding Round
$132 M (USD), Series B
Jul 29, 2025
-
Investors
ARE
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ARTBIO
ARTBIO offers a comprehensive portfolio of products and services, including AB001, AlphaDirect TM, and Pipeline Programs. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets prostate cancer with precise radiation treatment
Produces isotopes for advanced cancer therapies
Develops multiple therapies for various solid tumors
Unlock access to complete
Funding Insights of ARTBIO
ARTBIO has successfully raised a total of $245.3M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $132 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $132.0M
-
First Round
First Round
(21 Jun 2023)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2025 | Amount | Series B - ARTBIO | Valuation | Sofinnova Investments , B Capital | |
| Dec, 2023 | Amount | Series A - ARTBIO | Valuation | Third Rock Ventures | |
| Jun, 2023 | Amount | Seed - ARTBIO | Valuation | F-Prime Capital , Omega Funds |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ARTBIO
ARTBIO has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Third Rock Ventures and F-Prime Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital funding is provided to early-stage life science companies.
|
Founded Year | Domain | Location | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Founded Year | Domain | Location | |
|
Venture capital firm
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ARTBIO
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ARTBIO
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Artbio Comparisons
Competitors of ARTBIO
ARTBIO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advanced Accelerator Applications, SOFIE, AdvanCell, Ariceum Therapeutics and Mariana Oncology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Developer of molecular imaging systems and radio-pharmaceuticals
|
|
| domain | founded_year | HQ Location |
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment
|
|
| domain | founded_year | HQ Location |
Developer of drugs for systemic targeted radiation therapy to treat cancer
|
|
| domain | founded_year | HQ Location |
Targeted radiopharmaceuticals for solid tumors are developed and pioneered.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Artbio
Frequently Asked Questions about ARTBIO
When was ARTBIO founded?
ARTBIO was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Where is ARTBIO located?
ARTBIO is headquartered in Sacramento, United States. It is registered at Sacramento, California, United States.
Who is the current CEO of ARTBIO?
Emanuele Ostuni is the current CEO of ARTBIO.
Is ARTBIO a funded company?
ARTBIO is a funded company, having raised a total of $245.3M across 3 funding rounds to date. The company's 1st funding round was a Seed of $23.3M, raised on Jun 21, 2023.
What does ARTBIO do?
ARTBIO was founded in 2021 and is based in Sacramento, United States. Alpha radioligand therapies for cancer treatment are developed by the company, with lead-212 employed as the primary alpha-emitting isotope. Operations focus on targeted radioligand applications in oncology. The lead program, AB001, is directed toward prostate cancer. Co-founders include Roy H. Larsen and Oyvind Bruland, with Emanuele Ostuni serving as CEO.
Who are the top competitors of ARTBIO?
ARTBIO's top competitors include Advanced Accelerator Applications, SOFIE and AdvanCell.
What products or services does ARTBIO offer?
ARTBIO offers AB001, AlphaDirect TM, and Pipeline Programs.
Who are ARTBIO's investors?
ARTBIO has 7 investors. Key investors include ARE, Third Rock Ventures, F-Prime Capital, Omega Funds, and Sofinnova.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.